Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3668361 | 0.98 | GNAI3 (0.62) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| SCHEMBL4030838 | 0.86 | KEAP1 (0.58) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| SCHEMBL3973508 | 0.85 | ALOX15 (0.60) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| SCHEMBL5324155 | 0.84 | GNAI3 (0.57) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29056645 | 0.84 | KEAP1 (0.56) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3673025 | 0.83 | ALOX15 (0.57) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| SCHEMBL23448772 | 0.81 | GNAI3 (0.59) | GNAI3GNAO1GNAI1SMN1; SMN2SPHK1 | |
| SCHEMBL1290862 | 0.79 | CARM1 (0.52) | KEAP1SMN1; SMN2SIGMAR1HRH3 | |
| SCHEMBL4035833 | 0.79 | KEAP1 (0.50) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 | |
| SCHEMBL2297876 | 0.79 | KEAP1 (0.50) | GNAI3GNAO1GNAI1KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101500594-A | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | SIRION THERAPEUTICS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| WO-2009052708-A1 | 1-(3-AMINO-PROPYL)-PIPERIDIN-4-YL-AMIDES, PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR THEIR PREPARATION AND USES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009052708-A1 | 1-(3-AMINO-PROPYL)-PIPERIDIN-4-YL-AMIDES, PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR THEIR PREPARATION AND USES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2009-04-30 | — | — | WO | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | GNAI3 1816/4885GNAO1 407/4885GNAI1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.